

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX CORP.

Petitioner

v.

ALCON RESEARCH, LTD.

Patent Owner

---

CASE IPR2013-00428

U.S. Patent No. 8,268,299

---

**APOTEX CORP.'S EXHIBIT LIST**

***Mail Stop "PATENT BOARD"***

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

**APOTEX CORP. EXHIBIT LIST**  
CASE IPR2013-00428

<i>Apotex Exhibit #</i>	<i>Description</i>
<b>1001</b>	Kabra <i>et al.</i> , U.S. Patent No. 8,268,299, "Self Preserved Aqueous Pharmaceutical Compositions" (filed September 20, 2007; issued September 18, 2012)
<b>1002</b>	Declaration of Michael J. Miller, Ph.D.
<b>1003</b>	Xia <i>et al.</i> , WO 2005/097067, "Zinc Preservative Composition and Method of Use" (filed March 24, 2005; published October 20, 2005)
<b>1004</b>	Chowhan <i>et al.</i> , U.S. Patent No. 6,143,799, "Use of Borate-Polyol Complexes in Ophthalmic Compositions" (filed July 2, 1998; issued November 7, 2000)
<b>1005</b>	Gadd <i>et al.</i> , "Microorganisms and Heavy Metal Toxicity," <i>Microbial Ecology</i> , 4:303-317 (1978)
<b>1006</b>	FDA Approved Drug Label "TRAVATAN <sup>®</sup> (travoprost ophthalmic solution) 0.004% Sterile" (2001)
<b>1007</b>	Certified English translation of Kiyobayashi, JP 2003-104870, "Aqueous Composition" (filed September 28, 2001; issued April 9, 2003)
<b>1008</b>	File history of U.S. Patent No. 8,268,299 (as of July 5, 2013, and exclusive of foreign patent documents listed in Information Disclosure Statements)
<b>1009</b>	Kiyobayashi, JP 2003-104870, "Aqueous Composition" (filed September 28, 2001; published April 9, 2003)
<b>1010</b>	File history of U.S. Patent No. 8,323,630 (as of July 5, 2013, and exclusive of foreign patent documents listed in Information Disclosure Statements)
<b>1011</b>	File history of U.S. Patent No. 8,388,941 (as of July 5, 2013, and exclusive of foreign patent documents listed in Information Disclosure Statements)
<b>1012</b>	Sheftel, "Indirect Food Additives and Polymers: Migration and Toxicology," p. 422 (2000)

**APOTEX CORP. EXHIBIT LIST**  
CASE IPR2013-00428

<i><b>Apotex Exhibit #</b></i>	<i><b>Description</b></i>
<b>1013</b>	The European Agency for the Evaluation of Medicinal Products, <i>Veterinary Medicines Evaluation Unit</i> , "Polyoxyl Castor Oil, Polyoxyl Hydrogenated Castor Oil Summary Report" (1999)
<b>1014</b>	"Antimicrobial Effectiveness Testing," in The United States Pharmacopeia 26: The National Formulary 22, pp. 2002-2004 (2003)
<b>1015</b>	<i>Curriculum Vitae</i> of Michael J. Miller, Ph.D.
<b>1016</b>	FORM 6-K, SECURITIES AND EXCHANGE COMMISSION, For the month of May 2002, ALCON, INC.
<b>1017</b>	Affidavit in Support of Motion for <i>Pro Hac Vice</i> Admission of Paul A. Ainsworth Under 37 C.F.R. § 42.10(c)
<b>1018</b>	Affidavit in Support of Motion for <i>Pro Hac Vice</i> Admission of H. Keeto Sabharwal Under 37 C.F.R. § 42.10(c)

Respectfully submitted,

/Eldora L. Ellison/

Date: February 4, 2014  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
1807447\_1

Eldora L. Ellison, Ph.D.  
Lead Attorney for Petitioner, Apotex Corp.  
Registration No. 39,967

**APOTEX CORP. EXHIBIT LIST**  
CASE IPR2013-00428

**CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))**

The undersigned hereby certifies that the above-captioned “Apotex Corp.’s Exhibit List” and Exhibit 1018 were served in their entirety on February 4, 2014, upon the following parties via email:

Stanley E. Fisher  
[sfisher@wc.com](mailto:sfisher@wc.com)  
Williams & Connolly, LLP

Barry L. Copeland  
[barry.copeland@alcon.com](mailto:barry.copeland@alcon.com)  
[patent.docketing@alcon.com](mailto:patent.docketing@alcon.com)  
Alcon Research, Ltd.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/Eldora L. Ellison/

Date: February 4, 2014  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

Eldora L. Ellison, Ph.D.  
Lead Attorney for Petitioner, Apotex Corp.  
Registration No. 39,967